Regional celiac artery infusion as adjuvant treatment after pancreatic cancer resection.

  title={Regional celiac artery infusion as adjuvant treatment after pancreatic cancer resection.},
  author={Karl H. Link and Andrea Formentini and Frank Gansauge and E. Papachristov and Hans G. Beger},
  volume={58 6},
BACKGROUND/AIMS The dismal course of pancreatic adenocarcinoma patients after resection is determined by the biology of the disease preventing R-0 resections. In the spontaneous course after resection, patients frequently develop either local recurrences, liver metastases and/or peritoneal metastases. Postoperative radiochemotherapy may extend survival and reduce local recurrences without influence on hepatic progression. We performed adjuvant celiac artery infusion in pancreatic cancer, to… 

Adjuvant therapy in pancreatic cancer: historical and current perspectives.

The European Study Group for Pancreatic Cancer (ESPAC)-1 trial demonstrated that the current best adjuvant treatment is chemotherapy using bolus 5-fluorouracil with folinic acid, which is as good or superior to multimodality treatments including intra-operative radiotherapy, adjUvant chemoradiotherapy and neo-adjuvant therapies.

Marginal effects of regional intra-arterial chemotherapy as an alternative treatment option in advanced pancreatic carcinoma

Despite conceptual and pharmacokinetic advantages of locoregional i.a. chemotherapy, better outcome with regard to tumour response rate and survival time could not be found and is, therefore, still an experimental treatment option in pancreatic carcinoma and can, currently, not be recommended for routine use.

New Techniques and Agents in the Adjuvant Therapy of Pancreatic Cancer

Currently, the best treatment is with 5-fluorouracil with folinic acid, but in the light of ongoing clinical trials, this may be supplanted by gemcitabine as the treatment of choice.

Pancreatic cancer — Adjuvant therapy

There is a clear cut survival advantage however with chemotherapy compared to observation, based on the results from two large randomized controlled trials, and supported by an individual patient data meta-analysis.

Emerging drugs in pancreatic cancer

Preclinical and Phase I and II studies of cyclooxygenase-2 or lipoxygenases inhibitors, various immunotherapeutic approaches and several tyrosine kinase inhibitors or monoclonal antibodies against growth factors or their receptors are encouraging and may provide some hope for patients with pancreatic cancer.

The role of adjuvant therapy for pancreatic cancer

The results of large-scale randomised controlled trials to assess adjuvant therapies for pancreatic cancer demonstrate the great surgical and oncological progress made over the past decade.

Adjuvant treatment.

The main trials of adjuvant chemotherapy, chemoradiotherapy and chemoradaotherapy with follow-on chemotherapy are described in this paper, followed by the results of the ESPAC-1 trial and the status of ESPAC -2 and -3 trials.

Analysis of liver metastasis after resection for pancreatic ductal adenocarcinoma.

Tumor size is the key indicator for LM after resection of PDAC, which occurs early and shows poor survival in low-risk groups.